![]() ![]() On September 13, 2021, Silverback issued a press release "announc that interim data from the dose-escalation portion of its Phase 1/ 1b clinical trial evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors" were to be presented from September 16-21, 2021. ![]() On or about December 3, 2020, Silverback conducted its IPO, offering 11,500,000 shares of its common stock to the public at a price of $21 per share for anticipated proceeds of approximately $241,500,000.Īccording to the complaint, Defendants made false and/or misleading statements and failed to disclose that (i) Silverback's lead product candidate SBT6050 was less effective than the Company had represented to investors and (ii) the Company had overstated SBT6050's commercial and/or clinical prospects. Shareholder Class Action Lawsuit or contact Joe Seidman toll free at (877) 779-1414 or. If you purchased or acquired (a) Silverback common stock in connection with the IPO and/or (b) Silverback securities during the Class Period, and/or would like to discuss your legal rights and options please visit Silverback Therapeutics Inc. The lawsuit was filed in the United States District Court for the Western District of Washington and alleges violations of §§11 and 15 of the Securities Act of 1933 and §§ 10(b) and 20(a) of the Securities Exchange Act of 1934. ("Silverback" or the "Company") (NASDAQ: SBTX) in connection with Silverback's Deceminitial public offering and/or (ii) Silverback securities between Decemand September 10, 2021, inclusive (the "Class Period"). 9, 2021 /PRNewswire/ - Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired (i) the common stock of Silverback Therapeutics, Inc. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |